within Pharmacolibrary.Drugs.ATC.N;

model N07XX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.0006666666666666666,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.08,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07XX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Xaliproden is a serotonin 5-HT1A receptor agonist developed for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Although it has shown neuroprotective activity in preclinical studies, it is not approved for medical use as clinical trials failed to demonstrate sufficient efficacy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for an adult population, assumed healthy volunteers, based on preclinical and phase I/II summaries due to absence of detailed peer-reviewed published PK data.</p><h4>References</h4><ol><li><p>Bourrié, B, et al., &amp; Casellas, P (1999). The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> 96(22) 12855–12859. DOI:<a href=\"https://doi.org/10.1073/pnas.96.22.12855\">10.1073/pnas.96.22.12855</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10536012/\">https://pubmed.ncbi.nlm.nih.gov/10536012</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07XX03;
